These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 29432822)
1. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects. Zuwala K; Riber CF; Løvschall KB; Andersen AHF; Sørensen L; Gajda P; Tolstrup M; Zelikin AN J Control Release; 2018 Apr; 275():53-66. PubMed ID: 29432822 [TBL] [Abstract][Full Text] [Related]
2. Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity. Riber CF; Hinton TM; Gajda P; Zuwala K; Tolstrup M; Stewart C; Zelikin AN Mol Pharm; 2017 Jan; 14(1):234-241. PubMed ID: 28043136 [TBL] [Abstract][Full Text] [Related]
3. Macromolecular prodrugs of ribavirin: concerted efforts of the carrier and the drug. Smith AA; Wohl BM; Kryger MB; Hedemann N; Guerrero-Sanchez C; Postma A; Zelikin AN Adv Healthc Mater; 2014 Sep; 3(9):1404-7. PubMed ID: 24408515 [TBL] [Abstract][Full Text] [Related]
4. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation. Wohl BM; Smith AA; Jensen BE; Zelikin AN J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544 [TBL] [Abstract][Full Text] [Related]
5. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect. Guo H; Sun S; Yang Z; Tang X; Wang Y J Control Release; 2015 Jul; 209():27-36. PubMed ID: 25883028 [TBL] [Abstract][Full Text] [Related]
6. Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity. Hinton TM; Zuwala K; Deffrasnes C; Todd S; Shi S; Marsh GA; Dearnley M; Wohl BM; Tolstrup M; Zelikin AN Adv Healthc Mater; 2016 Mar; 5(5):534-40. PubMed ID: 26789641 [TBL] [Abstract][Full Text] [Related]
7. Macromolecular prodrugs for controlled delivery of ribavirin. Kryger MB; Smith AA; Wohl BM; Zelikin AN Macromol Biosci; 2014 Feb; 14(2):173-85. PubMed ID: 24105953 [TBL] [Abstract][Full Text] [Related]
8. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs. Wohl BM; Smith AA; Kryger MB; Zelikin AN Biomacromolecules; 2013 Nov; 14(11):3916-26. PubMed ID: 24156371 [TBL] [Abstract][Full Text] [Related]
9. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug. Kryger MB; Wohl BM; Smith AA; Zelikin AN Chem Commun (Camb); 2013 Apr; 49(26):2643-5. PubMed ID: 23431562 [TBL] [Abstract][Full Text] [Related]
10. Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells. Ruiz-Sanchis P; Wohl BM; Smith AA; Zuwala K; Melchjorsen J; Tolstrup M; Zelikin AN Adv Healthc Mater; 2015 Jan; 4(1):65-8. PubMed ID: 25132665 [TBL] [Abstract][Full Text] [Related]
11. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. Ishihara T; Kaneko K; Ishihara T; Mizushima T J Pharm Sci; 2014 Dec; 103(12):4005-4011. PubMed ID: 25335768 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. Dong Z; Li Q; Guo D; Shu Y; Polli JE J Pharm Sci; 2015 Sep; 104(9):2864-76. PubMed ID: 25645375 [TBL] [Abstract][Full Text] [Related]
13. Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment. Craparo EF; Teresi G; Licciardi M; Bondí ML; Cavallaro G J Biomed Nanotechnol; 2013 Jun; 9(6):1107-22. PubMed ID: 23858977 [TBL] [Abstract][Full Text] [Related]
14. Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes. Craparo EF; Triolo D; Pitarresi G; Giammona G; Cavallaro G Biomacromolecules; 2013 Jun; 14(6):1838-49. PubMed ID: 23621358 [TBL] [Abstract][Full Text] [Related]
15. Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs. Frich CK; Krüger F; Walther R; Domar C; Andersen AHF; Tvilum A; Dagnæs-Hansen F; Denton PW; Tolstrup M; Paludan SR; Münch J; Zelikin AN J Control Release; 2019 Jan; 294():298-310. PubMed ID: 30552954 [TBL] [Abstract][Full Text] [Related]
16. Glutathione and Reactive Oxygen Species Dual-Responsive Block Copolymer Prodrugs for Boosting Tumor Site-Specific Drug Release and Enhanced Antitumor Efficacy. Yin W; Ke W; Lu N; Wang Y; Japir AAMM; Mohammed F; Wang Y; Pan Y; Ge Z Biomacromolecules; 2020 Feb; 21(2):921-929. PubMed ID: 31961134 [TBL] [Abstract][Full Text] [Related]
17. Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release. Du L; Wu L; Jin Y; Jia J; Li M; Wang Y Int J Pharm; 2014 Sep; 472(1-2):1-9. PubMed ID: 24929012 [TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of a pterostilbene-peptide prodrug nanomedicine for the management of dry eye. Hu L; Hu Z; Yu Y; Ding X; Li K; Gong Q; Lin D; Dai M; Lu F; Li X Int J Pharm; 2020 Oct; 588():119683. PubMed ID: 32712251 [TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery. Kumar S; Sharma B; Bhardwaj TR; Singh RK Anticancer Agents Med Chem; 2021; 21(3):383-392. PubMed ID: 32781967 [TBL] [Abstract][Full Text] [Related]